MIFH
JUNO

Migdal Insurance & Financial Holdings’s Juno Therapeutics, Inc. JUNO Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-118
Closed -$2K – 512
2016
Q4 		$2K Buy
+118
New +$2.89K ﹤0.01% 412

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Migdal Insurance & Financial Holdings's JUNO Position: Q1 2017 in Review

Migdal Insurance & Financial Holdings sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 118 shares — an estimated $2K sold.

Migdal Insurance & Financial Holdings first reported a position in JUNO in Q4 2016 and held it in 1 quarter. The position peaked at $2K in Q4 2016. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

  • Migdal Insurance & Financial Holdings reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 118 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $2K.
  • Migdal Insurance & Financial Holdings first reported a position in Juno Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • Migdal Insurance & Financial Holdings's Juno Therapeutics, Inc. position peaked at $2K in Q4 2016.
  • 157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2017, filed 15 May 2017.